Publications by authors named "Harshad Kulkarni"

Are you Harshad Kulkarni?   Register this Author

Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms.
Oncotarget 2018 Mar 15;9(24):16932-16950. Epub 2018 Feb 15.
Department of Gastroenterology/Endocrinology, Center for Neuroendocrine Tumors Bad Berka - ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany.




Localization of Radiolabeled Somatostatin Analogs in the Spleen.
Clin Nucl Med 2016 Feb;41(2):e111-4
From the *Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands; †Department of General and Visceral Surgery, and ‡Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka; §Institute of Pharmacology and Toxicology, Jena University Hospital, Jena; ∥Laboratory of Pathology and Cytology, Zentralklinik Bad Berka, Bad Berka, Germany; and ¶Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.


First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Cancer Biother Radiopharm 2015 May;30(4):152-9
1 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, ENETS Center of Excellence , Bad Berka, Germany .

THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.
Ann Transl Med 2014 Jan;2(1)
1 Internal Medicine/Gastroenterology and Endocrinology, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, Germany ; 2 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, BRD, Germany.

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging 2011 Sep 31;38(9):1659-68. Epub 2011 May 31.
Department of General and Visceral Surgery, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, Germany.


Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med 2017 01;376(2):125-135
From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.).

OF